At a glance

Cognitive enhancement / focus
Neuroprotection (stroke / TBI support)
BDNF / neuroplasticity upregulation
Mood / anxiety support
Anxiety / mood destabilisation
Sleep disturbance
Blood-pressure / cardiovascular
Product quality / contamination risk
BenefitSide effectHealth risk· more & brighter bars = stronger

Effects

  • Cognitive enhancement: A 1996 controlled study in healthy subjects found doses of 250–1,000 µg improved attention and short-term memory, with effects maximised under fatigue conditions [4].
  • Neuroprotection / stroke support: In Russian clinical use, Semax is approved for acute ischaemic stroke and traumatic brain injury; a 2018 trial in 110 stroke patients showed increased plasma BDNF and improved rehabilitation timing [4][7].
  • BDNF / neurotrophic upregulation: A single 50 µg/kg dose produces a ~1.4-fold increase in BDNF protein and a 3-fold rise in BDNF mRNA in hippocampal tissue in preclinical models [4].
  • Mood / anxiolytic potential: Animal studies show antidepressant-like and anxiolytic-like effects via serotonergic and BDNF pathways; small Russian trials report mood-buffering effects, though it is not formally approved for any mood disorder [2][5].
  • Fatigue resilience / focus: Some clinicians explore low-dose Semax for cognitive fatigue, ADHD, and 'brain fog', aiming to improve focus and reduce mental fatigue [7].
Classification

Synthetic neuropeptide / nootropic (ACTH fragment analogue)

Active half-life

Parent: ~2–5 min plasma; active metabolite Pro-Gly-Pro extends functional effects to hours [6]

Route

Intranasal (primary); subcutaneous studied in animals; oral bioavailability is effectively zero [6]

Regulatory status

Approved pharmaceutical in Russia/CIS; not FDA/EMA approved — research compound only in US, UK, EU [2][5]

Onset

CSF concentrations rise within ~30 minutes of intranasal dose [6]